Insulin growth factor-based dosing of growth hormone therapy in children: A randomized, controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 7, 2007, Pages 2480-2486

  Cohen, Pinchas ^a   Rogol, Alan D ^b   Howard, Campbell P ^c   Bright, George M ^c,f   Kappelgaard, Anne Marie ^d   Rosenfeld, Ron G ^e  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NOVO NORDISK INC   (United States)

^d NOVO NORDISK A S   (Denmark)

^e LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^f Tercica Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; BODY HEIGHT; CHILD; CHILD GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE PAIN; FEASIBILITY STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; HEMATOMA; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; INTRACRANIAL HYPERTENSION; LOW DRUG DOSE; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPEN STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCOLIOSIS; SCORING SYSTEM; SHORT STATURE; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION;

EID: 34447119568     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0204     Document Type: Article

References (39)

1. Raben MS 1958 Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 18:901-903
2. Raben MS 1962 Clinical use of human growth hormone. N Engl J Med 266:82-86
3. Vance ML, Mauras N 1999 Growth hormone therapy in adults and children. N Engl J Med 341:1206-1216
4. 2000 Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85:3990-3993
5. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG 2002 Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 87:90-98
6. de Muinck Keizer-Schrama SM, Rikken B, Wynne HJ, Hokken-Koelega AC, Wit JM, Bot A, Drop SL 1992 Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group. J Clin Endocrinol Metab 74:898-905
7. Frasier SD, Costin G, Lippe BM, Aceto Jr T, Bunger PF 1981 A dose-response curve for human growth hormone. J Clin Endocrinol Metab 53:1213-1217
8. Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard HW, Seibel JA, Vance ML, Zimmerman D, Palumbo PJ, Bergman DA, Garber JR, Hamilton Jr CR, Petak SM, Rettinger HI, Service FJ, Shankar TP, Stoffer SS, Tourletot JB 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children - 2003 update. Endocr Pract 9:64-76
9. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797
10. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J 2000 High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 85:3653-3660
11. Baker J, Liu JP, Robertson EJ, Efstratiadis A 1993 Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73-82
12. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A 1993 Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72
13. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ 1996 Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 335:1363-1367
14. Woods KA, Camacho H, Barter D, Clark AJ, Savage MO 1997 Insulin-like growth factor I gene deletion causing intrauterine growth retardation and severe short stature. Acta Paediatr Suppl 423:39-45
15. Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K 1996 Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. J Clin Endocrinol Metab 81:3902-3908
16. Kamp GA, Zwinderman AH, Van Doorn J, Hackeng W, Frolich M, Schonau E, Wit JM 2002 Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin Endocrinol (Oxf) 57:315-325
17. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566
18. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396
19. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625
20. 2001 Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 86:1868-1870
21. Cohen P, Clemmons DR, Rosenfeld RG 2000 Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 10:297-305
22. Ogilvy-Stuart AL, Gleeson H 2004 Cancer risk following growth hormone use in childhood: implications for current practice. Drug Saf 27:369-382
23. Swerdlow AJ, Higgins CD, Adlard P, Preece MA 2002 Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 360:273-277
24. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robison LL 2002 Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 87:3136-3141
25. 1997 World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925-926
26. Marshall WA, Tanner JM 1969 Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291-303
27. Marshall WA, Tanner JM 1970 Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:13-23
28. Greulich W, Pyle S 1959 Radiographic atlas of skeletal development of the hand and wrist. Stanford, CA: Stanford University Press
29. Ranke MB, Lindberg A, Martin DD, Bakker B, Wilton P, Albertsson-Wikland K, Cowell CT, Price DA, Reiter EO 2003 The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 88:4748-4753
30. Ranke MB, Lindberg A, Cowell CT, Wikland KA, Reiter EO, Wilton P, Price DA 2003 Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab 88:125-131
31. Schonau E, Westermann F, Rauch F, Stabrey A, Wassmer G, Keller E, Bramswig J, Blum WF 2001 A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol 144:13-20
32. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML 2004 Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 89:3224-3233
33. Dos SC, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P 2004 A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720-724
34. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfaffle R, Raile K, Seidel B, Smith RJ, Chernausek SD 2003 IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 349:2211-2222
35. Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, Rundle AC, Wells JA, Carlsson LM 1995 Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med 333:1093-1098
36. Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler Jr GB, Baron J 2004 Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 89:3140-3148
37. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A 2001 Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 229:141-162
38. Park P, Cohen P 2005 Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res 15(Suppl A):S13-S20
39. Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, Gill A, Chaussain JL, Frisch H, Yturriaga R, Attanasio AF 2005 Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr 146:45-53